

**Response letter**

Dear Editors and Reviewers:

Thank you for your letter and for the comments concerning our manuscript "Title: Effect of rifampicin on anticoagulation of warfarin: A case report and literature review"(ID: 57344). Those comments are all valuable and very helpful for revising and improving our paper, as well as the importance guiding significance to our researches.

We have studied these comments carefully and tried our best to revise and improve the manuscript.

The main corrections in the paper and the responds to the reviewer's comments are listed below this letter.

Thanks for your helpful suggestions.

With best regards,

Yours sincerely,

Bo-Ting Zhou

## **Response to the reviewer 2 comments**

[This case report and review of cases in the literature looks at the concept of drug interaction between warfarin and rifampicin and how to manage it. The novel factors in this case are (i) that the baseline condition requiring rifampicin was brucellosis, not TB, and (ii) The involvement of pharmacy led dose titration. It also highlights differences in patients characteristics, namely Chinese racial origin and vitamin K rich diet, that might impact warfarin dosing.

Whilst the manuscript is well written and has some novel features as described above the main messages about drug interaction and how to monitor and adjust are not new. The conclusions adequately support the data provided. The manuscript addresses the issue of multidisciplinary working well.]

**Response:** Thank you for your approval and comments on our manuscript. We have reconsidered the novelty of our manuscript. Just as you listed above, we described drug interactions between warfarin and rifampicin in a patient with brucellosis and pharmacists are leaders in dosage adjustment. Also, the dose adjustment process including the initial dose and the target therapeutic range was different from cases reported before because of the patient's characteristics. But we have to admit that the drug interaction and how to monitor and adjust are relatively not new. We adopted the traditional dose adjustment and provided 10-month pharmaceutical care.

### **Response to science editor**

Issues raised (1) I found the title was more than 18 words. The title should be no more than 18 words; (2) I found no "Author contribution" section. Please provide the author contributions; (3) I found no "Corresponding author" section. Please provide the corresponding author section; (4) I found the authors did not provide the original figures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor; (5) I found the authors did not add the PMID and DOI in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout; (6) I found the "Case Presentation" did not meet our requirements. Please re-write the "Case Presentation" section, and add "FINAL DIAGNOSIS", "TREATMENT", and "OUTCOME AND FOLLOW-UP" section to the main text, according to the Guidelines and Requirements for Manuscript Revision; (7) the author should number the references in Arabic numerals according to the citation order in the text. The reference numbers need to be superscripted in square brackets at the end of the sentence before the punctuation or after the cited author's name, with no spaces; (8) please write the "Core Tip" section following the "Key Words" section. Please also provide the audio core tip file where the content of core tip is recorded; (9) please provide a running title for the manuscript; and (10) please provide the signed Copyright License Agreement with the signatures of all authors in the same order as in the manuscript.

**Response:** Thank you for your comment to improve the quality of our manuscript. We have made changes in accordance with the issue raised, and the details of the changes are as follows:

(1) We changed the title to "Effect of rifampicin on anticoagulation of warfarin: A case report and literature review".

(2) Author contribution was added and the details was "Author contributions: Hu YN and Zhou BT were the patient's pharmacists. Hu YN reviewed the literature and contributed to manuscript drafting. Hu YN, Zhou BT, Yang HR, Peng QL and Gu XR integrated the information from the patient and contributed to the figure. Zhou BT and Sun SS were responsible for revision of the manuscript. All authors commented on previous versions of the manuscript. The major reviewing and editing were completed by Zhou BT and Hu YN. All authors issued final approval for the version to be submitted."

(3) Corresponding section was provided and the specific information of the corresponding author was Bo-Ting Zhou, PhD, Chief Pharmacist, Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. [botingzhou0918@126.com](mailto:botingzhou0918@126.com).

(4) The original figure 1 was uploaded to the system in PPT format. But this figure was originally drawn by graphpad software. If you want to edit the original data, you can contact me to get the PRISM format.

(5) The reference format has been changed in accordance with the guidelines. PMID and DOI were also provided. The details was started in page 10 line 18.

(6) The "Case Presentation" section was re-write according to the Guidelines and Requirements for Manuscript Revision. You can find the re-write text in page 5 line 12.

(7) The reference numbers were changed to format according to the guideline.

(8) "Core Tip" section was inserted following the "Key Words" section and the audio core tip was recorded and uploaded in the system. It is in page 3 line 26.

(9) The running title was "Hu YN et al. Effect of rifampicin on anticoagulation of warfarin". It is in page 1 line 8.

(10) The signed Copyright License Agreement with the signatures of all

authors in the same order as in the manuscript was uploaded in the system.

**Response to company editor-in-chief**

[I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. However, the quality of the English language of the manuscript does not meet the requirements of the journal. Before final acceptance, the author(s) must provide the English Language Certificate issued by a professional English language editing company.]

**Response:** Thank you for your comment to improve the quality of our manuscript. We carefully polished the language of our manuscript, including the title, abstract, core tip, introduction, materials and methods, results, discussion. All sentences and paragraphs are organized in a logical manner. We also sent it to a professional English language editing company and GRADE A English Language Certificate was got.